Growth Hormone Therapy Explored for Early Intervention in Turner Syndrome Girls

Turner Syndrome is a genetic condition affecting girls, characterized by the absence or partial absence of one of the X chromosomes. A primary symptom is short stature, often significantly impacting quality of life and psychosocial development. While growth hormone (GH) therapy is a known treatment to improve height, its efficacy when initiated very early in life, specifically before the age of 4 years, needed further investigation to optimize long-term height outcomes and establish best practice guidelines.

The provided research record, an abstract from a clinical trial registry, does not contain specific numerical results regarding the efficacy of r-hGH treatment. However, the study was designed to assess the impact of early intervention on growth parameters in girls with Turner Syndrome. The primary objective was to evaluate whether starting r-hGH therapy before the age of 4 could significantly improve height velocity and potentially increase final adult height compared to later initiation or no treatment. The completion of this Phase 4 study, spanning 18 years, suggests a comprehensive evaluation of r-hGH's long-term effects on growth in this vulnerable population. While specific data is not available in this record, the study's design aimed to provide insights into optimal treatment timing, with the expectation that early intervention could lead to more substantial improvements in growth. > While specific data is not available in this record, the completion of this Phase 4 study suggests a comprehensive evaluation of r-hGH's long-term effects on growth in this vulnerable population.